New Diabetes Drug that also lowers body weight and blood pressure
This new drug, is the first of a new class of Diabetes drugs that acts like no other, since it rids excess glucose from the organism without interfering with insulin action and can be used in combination with other medications to provide optimal blood glucose and Hemoglobin A1c levels control. This medicine also helps reduce excess body weight and high blood pressure levels.
By Joe Cardozo
The European Commission (EC) approved the use and marketing of Dapagliflozin within the European Union, which is the first SGLT2 inhibitor to be to be approved for Type 2 Diabetes. On January 8th, 2014 Dapagliflozin was approved by the FDA for its use in America. SGLT2 inhibitors (Sodium-Glucose cotransporter 2 inhibitor), act in a novel and unique way in relation to other types of Type 2 Diabetes drugs that exist today.
SGLT inhibitors are pharmaceutical products that block the action of the SGLT protein, allowing unused glucose that has been filtered by the kidneys, to be expelled through urination.
Why is it important to block SGLT protein action in people with Diabetes?
The Glucose Sodium-dependent SGLT or Transporters are transport proteins in charge of reabsorbing glucose, which would’ve otherwise been excreted in the urine, to accumulate as an energy reserve in the human body.
In people without Diabetes, SGLT proteins are very useful, because that’s how the body gets the energy reserves it needs for normal development.
Unfortunately, SGLT transporters work exactly the same in people with Diabetes, which is why the body reabsorbs glucose it hasn’t used and it doesn’t expel it through urine, so the glucose that has already been filtered by the kidneys returns to the blood, further raising blood sugar levels.
There are two types of SGLT protein, both act from the kidneys and are SGLT1, which absorbs 10% of all unused glucose and SGLT2 which is responsible for reabsorbing the remaining 90%, which has already been filtered by the kidneys.
By blocking SGLT2 protein action, the body will expel the 90% excess glucose through the urine, significantly reducing blood glucose levels.
Dapagliflozin is a SGLT2 protein inhibitor
Dapagliflozin, approved under the trade name Forxiga™ and marketed by AstraZeneca and Bristol Myers Squibb, is a selective SGLT2 inhibitor that works independently from insulin to remove excess glucose from the body. This treatment is unique and no other Diabetes treatment acts this way. Forxiga™ in tablets has to be taken once a day and be used with a good diet and exercise or in combination with other oral hypoglycemic agents or insulin, so the patient can achieve optimal control of their blood glucose and Hemoglobin A1c levels.
Clinical trials with the drug, showed that it also reduces body weight and lowers blood pressure.
Results of the scientific study before approval of Forxiga™
Before Dapagliflozin was approved, a scientific study was done that included 11 randomized studies in which 5,693 patients worldwide participated divided in two groups. A group made up of 3,939 participants received Dapagliflozin, while the rest (1,754 participants) received a Placebo.
Clinical trials found that a greater proportion of the Dapagliflozin treated group managed to decrease their Glycated Hemoglobin (A1c) levels to ideal levels, that is 7% or less. The study also showed that Dapagliflozin has a very small risk of causing hypoglycemia, when used as monotherapy. Researchers also found that there are additional clinical benefits to this novel medicine such as reduced body weight and blood pressure.
“Many patients with Type 2 Diabetes don’t often achieve their treatment goals and have a higher risk of developing complications, which is why there’s a critical need for new treatment options,” said Dr. John Wilding, Medicine Professor and director of the Clinical Diabetes and Endocrinology Research Unit at the University Hospital Aintree in the UK, adding “Dapagliflozin provides physicians with a completely new alternative to help achieve the objective of glycemic control, as an adjunct to current therapeutic options in the management of metformin or insulin in these patients, while also providing additional clinical benefits such as weight reduction and lowering blood pressure ”
What are the SGLT-2 inhibitors currently available on the market?
SGLT-2 inhibitors can be administered by themselves or in combination with other Diabetes medications. The following table lists the different medications that contain both the SGLT-2 inhibitor by itself, as well as formulated in combination with other types of medicine:
|Invokamet||Canagliflozine y Metformin|
|Xigduo XR||Dapagliflozine and Extended Release Metformin|
|Glyxambi||Empagliflozine y Linagliptine|
At Diabetes Up to Date we are glad to have this new drug
At Diabetes Up to Date we celebrate the permanent scientific studies currently being conducted worldwide searching for new treatments for optimal Diabetes control which shed successful results, and that every day new medicines are released into the market which make Diabetes treatment increasingly safe, effective and reliable.
Millions of people with Type 2 Diabetes around the world can now be benefited by this new drug, to achieve excellent control of their blood glucose and Hemoglobin A1c levels, as well as other additional advantages offered by this new class of drugs.
Copyright © 2000 -2016- Diabetes Up to Date – All Rights Reserved
Total or partial reproduction of this article is prohibited